Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | REN | P00797 | 4/20 | 0.46 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489899 | 0.88 | PEPD (0.43) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL15223614 | 0.85 | ACE (0.49) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL15223626 | 0.84 | ACE (0.48) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL10556672 | 0.84 | ACE (0.66) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL10922522 | 0.84 | ACE (0.48) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL11124849 | 0.83 | ACE (0.68) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL11124851 | 0.83 | ACE (0.68) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL7373400 | 0.82 | ACE (0.44) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL6788979 | 0.82 | ACE (0.44) | ACERENPEPDHSD17B10KDM4E | |
| SCHEMBL14682292 | 0.82 | ACE (0.67) | ACERENPEPDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ACE 1738/4885REN 1174/4885PEPD 1952/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | ACE 1738/4885REN 1174/4885PEPD 1952/4885 |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | ACE 1738/4885REN 1174/4885PEPD 1952/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | ACE 1712/4885REN 1145/4885PEPD 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.